Obesity Interventions | US | 2016 | Market Analysis
Growth in the US obesity intervention market will be limited because bariatric surgery procedure volumes will slightly decline over the forecast period. The difficulty associated with gaining FDA approval for novel devices will also limit the number of treatment options available to patients. However, the approvals of several new products in 2015 have the potential to lead to more device approvals over the forecast period as the FDA becomes more receptive to obesity treatments, thus supporting market growth.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the obesity interventions market in the US across a 10-year period.
